Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
Ichiro Sakuma(Hokko Memorial Hospital), Hiroaki Shimokawa(Tohoku University), Masahiro Kamouchi(Kyushu University), Shinichiro Uchiyama(International University of Health and Welfare), Takanori Ikeda(Toho University), Takeshi Yamashita(Cardiovascular Institute Hospital), Takanari Kitazono(Kyushu University), Hirotsugu Atarashi, Koji Fukuda(International University of Health and Welfare), Koichi Kaikita(Kumamoto University), Hideki Origasa(University of Toyama), Hiroshi Inoue(Toyama University Hospital), Wataru Shimizu(Nippon Medical School Hospital)
Cited by 24
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
|European Heart Journal|2018|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823